Zurich Cantonal Bank
AEGR

Zurich Cantonal Bank’s Aegerion Pharmaceuticals AEGR Stock Holding History

Zurich Cantonal Bank’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-546
Closed -$2K – 2579
2016
Q1 		$2K Hold
546
– – ﹤0.01% 2556
2015
Q4 		$6K Hold
546
– – ﹤0.01% 2511
2015
Q3 		$7K Buy
+546
New +$9.72K ﹤0.01% 2332

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Zurich Cantonal Bank's AEGR Position: Q2 2016 in Review

Zurich Cantonal Bank sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 546 shares — an estimated $2K sold.

Zurich Cantonal Bank first reported a position in AEGR in Q3 2015 and held it in 3 quarters. The position peaked at $7K in Q3 2015. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • Zurich Cantonal Bank reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Zurich Cantonal Bank sold 546 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $2K.
  • Zurich Cantonal Bank first reported a position in Aegerion Pharmaceuticals in Q3 2015 and held it in 3 quarters.
  • Zurich Cantonal Bank's Aegerion Pharmaceuticals position peaked at $7K in Q3 2015.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Zurich Cantonal Bank's 13F filing for Q2 2016, filed 1 Aug 2016.